<DOC>
	<DOCNO>NCT02173574</DOCNO>
	<brief_summary>The purpose Part 1 inform dose selection use alisporivir EDP239 combination obtain initial safety data co-administration alisporivir EDP239 support future treatment study patient . The purpose Part 2 inform drug-drug interaction potential EDP239 broadly possibly facilitate interpretation lower expect alisporivir concentration Part 1 , observe .</brief_summary>
	<brief_title>Two-way Interaction Between Alisporivir EDP239</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Male female subject 18 55 year age Body weight least 50 kg Women child bear potential Tobacco use History evidence inherit bilirubin disease disorder , include necessarily limit DubinJohnson Syndrome , Gilbert 's syndrome , Rotor Syndrome</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Hepatitis C Virus , Viral , Antiviral , Infection , Infectious disease , alisporivir , EDP239 , DEB025</keyword>
</DOC>